201. Isoprenylcysteine carboxyl methyltransferase (ICMT) promotes invadopodia formation and metastasis in cancer cells.
- Author
-
Borini Etichetti, Carla, Arel Zalazar, Evelyn, Di Benedetto, Carolina, Cocordano, Nabila, Valente, Sabrina, Bicciato, Silvio, Menacho-Márquez, Mauricio, Larocca, María Cecilia, and Girardini, Javier
- Subjects
- *
METASTASIS , *CANCER cells , *METHYLTRANSFERASES , *BIOCHEMICAL substrates , *CYTOSKELETON - Abstract
Isoprenyl cysteine carboxyl methyltransferase (ICMT) catalyzes the last step of the prenylation pathway. Previously, we found that high ICMT levels enhance tumorigenesis in vivo and that its expression is repressed by the p53 tumor suppressor. Based on evidence suggesting that some ICMT substrates affect invasive traits, we wondered if this enzyme may promote metastasis. In this work, we found that ICMT overexpression enhanced lung metastasis in vivo. Accordingly, ICMT overexpression also promoted cellular functions associated with aggressive phenotypes such as migration and invasion in vitro. Considering that some ICMT substrates are involved in the regulation of actin cytoskeleton, we hypothesized that actin-rich structures, associated with invasion and metastasis, may be affected. Our findings revealed that ICMT enhanced the formation of invadopodia. Additionally, by analyzing cancer patient databases, we found that ICMT is overexpressed in several tumor types. Furthermore, the concurrent expression of ICMT and CTTN , which encodes a crucial component of invadopodia, showed a significant correlation with clinical outcome. In summary, our work identifies ICMT overexpression as a relevant alteration in human cancer that promotes the development of metastatic tumors. • ICMT overexpression promotes metastasis in vivo. • ICMT enhances migration, invasion and invadopodia formation in cancer cells. • The ICMT gene is overexpressed in several human cancers. • High expression of ICMT and CTTN correlate with por clinical outcome in lung cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF